Abstract
The cell membrane P-glycoprotein (P-gp; MDR1, ABCB1) is an energy-dependent efflux pump that belongs to the ATP-binding cassette (ABC) family of transporters, and has been associated with drug resistance in eukaryotic cells. Multidrug resistance (MDR) is related to an increased expression and function of the ABCB1 (P-gp) efflux pump that often causes chemotherapeutic failure in cancer. Modulators of this efflux pump, such as the calcium channel blocker verapamil (VP) and cyclosporine A (CypA), can reverse the MDR phenotype but in vivo studies have revealed disappointing results due to adverse side effects. Currently available methods are unable to visualize and assess in a real-time basis the effectiveness of ABCB1 inhibitors on the uptake and efflux of ABCB1 substrates. However, predicting and testing ABCB1 modulation activity using living cells during drug development are crucial. The use of ABCB1-transfected mouse T-lymphoma cell line to study the uptake/efflux of fluorescent probes like ethidium bromide (EB), rhodamine 123 (Rh-123), and carbocyanine dye DiOC2, in the presence and absence of potential inhibitors, is currently used in our laboratories to evaluate the ability of a drug to inhibit ABCB1-mediated drug accumulation and efflux. Here we describe and compare three in vitro methods, which evaluate the permeability, transport kinetics of fluorescent substrates, and inhibition of the ABCB1 efflux pump by drugs of chemical synthesis or extracted from natural sources, using model cancer cell lines overexpressing this transporter, namely (1) real-time fluorimetry that assesses the accumulation of ethidium bromide, (2) flow cytometry, and (3) fluorescent microscopy using rhodamine 123 and DiOC2.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Saraswathy M, Gong S (2013) Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 31:1397–1407
Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14:3–9
Choudhuri S, Klaassen CD (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25:231–259
Goodman LS, Hardman JG, Limbird LE, Gilman AG (2001) Goodman & Gilman’s the pharmacological basis of therapeutics. McGraw-Hill, New York
Kimura Y, Morita SY, Matsuo M, Ueda K (2007) Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 98:1303–1310
Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749–757
Sarkadi B, Homolya L, Szakacs G, Varadi A (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 86:1179–1236
Taguchi Y, Kino K, Morishima M, Komano T, Kane SE, Ueda K (1997) Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry 36:8883–8889
Molnar J, Kars MD, Gunduz U, Engi H, Schumacher U, Van Damme EJ, Peumans WJ, Makovitzky J, Gyemant N, Molnar P (2009) Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp. Acta Histochem 111:329–333
Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152–162
Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–398
Eckford PD, Sharom FJ (2008) Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 47:13686–13698
Shustik C, Dalton W, Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1–78
Sharom FJ (2014) Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol 4:41
Yang K, Wu J, Li X (2008) Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends 2:137–146
Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, Lu QS, Singh S, Yang DH, Talele TT, Ambudkar SV, Chen ZS (2011) The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 6, e19329
Palmeira A, Sousa E, Vasconcelos MH, Pinto MM (2012) Three decades of P-gp inhibitors: skimming through several generations and scaffolds. Curr Med Chem 19:1946–2025
Eichhorn T, Efferth T (2012) P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs. J Ethnopharmacol 141:557–570
Zhu H, Liu Z, Tang L, Liu J, Zhou M, Xie F, Wang Z, Wang Y, Shen S, Hu L, Yu L (2012) Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells. Eur J Pharmacol 696:43–53
Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, Sharom FJ, Chaudhury S, Abdulhameed MD, Tawa G, Wallqvist A, Martinez R, Childers W, Abou-Gharbia M, Krynetskiy E, Andrade RB (2014) Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorg Med Chem 22:1148–1155
Lewandowska U, Gorlach S, Owczarek K, Hrabec E, Szewczyk K (2014) Synergistic interactions between anticancer chemotherapeutics and phenolic compounds and anticancer synergy between polyphenols. Postepy Hig Med Dosw (Online) 68:528–540
Martins C, Doran C, Silva IC, Miranda C, Rueff J, Rodrigues AS (2014) Myristicin from nutmeg induces apoptosis via the mitochondrial pathway and down regulates genes of the DNA damage response pathways in human leukaemia K562 cells. Chem Biol Interact 218:1–9
Dandawate P, Padhye S, Ahmad A, Sarkar FH (2013) Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res 3:165–182
Singh BN, Singh HB, Singh A, Naqvi AH, Singh BR (2014) Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade: phytoblockers of metastasis cascade. Cancer Metastasis Rev 33(1):41–85
Indumathy S, Dass CR (2013) Finding chemo: the search for marine-based pharmaceutical drugs active against cancer. J Pharm Pharmacol 65:1280–1301
Khushnud T, Mousa SA (2013) Potential role of naturally derived polyphenols and their nanotechnology delivery in cancer. Mol Biotechnol 55:78–86
Aggarwal B, Prasad S, Sung B, Krishnan S, Guha S (2013) Prevention and treatment of colorectal cancer by natural agents from mother nature. Curr Colorectal Cancer Rep 9:37–56
Nabekura T (2010) Overcoming multidrug resistance in human cancer cells by natural compounds. Toxins 2:1207–1224
Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE (2011) Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4:354–364
Dorai T, Aggarwal BB (2004) Role of chemopreventive agents in cancer therapy. Cancer Lett 215:129–140
Martins A, Toth N, Vanyolos A, Beni Z, Zupko I, Molnar J, Bathori M, Hunyadi A (2012) Significant activity of ecdysteroids on the resistance to doxorubicin in mammalian cancer cells expressing the human ABCB1 transporter. J Med Chem 55:5034–5043
Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS (2014) Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840:615–625
Gyemant N, Tanaka M, Antus S, Hohmann J, Csuka O, Mandoky L, Molnar J (2005) In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells. In Vivo 19:367–374
Du G, Lin H, Yang Y, Zhang S, Wu X, Wang M, Ji L, Lu L, Yu L, Han G (2010) Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. Int Immunopharmacol 10:819–826
Krishan A, Fitz CM, Andritsch I (1997) Drug retention, efflux, and resistance in tumor cells. Cytometry 29:279–285
Spengler G, Ramalhete C, Martins M, Martins A, Serly J, Viveiros M, Molnar J, Duarte N, Mulhovo S, Ferreira MJ, Amaral L (2009) Evaluation of cucurbitane-type triterpenoids from Momordica balsamina on P-glycoprotein (ABCB1) by flow cytometry and real-time fluorometry. Anticancer Res 29:3989–3993
Spengler G, Viveiros M, Martins M, Rodrigues L, Martins A, Molnar J, Couto I, Amaral L (2009) Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method. Anticancer Res 29:2173–2177
Viveiros M, Martins A, Paixao L, Rodrigues L, Martins M, Couto I, Fahnrich E, Kern WV, Amaral L (2008) Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int J Antimicrob Agents 31:458–462
Shapiro HM (2004) “Cellular astronomy” – a foreseeable future in cytometry. Cytometry A 60:115–124
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234
Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC (1988) A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A 85:4486–4490
Weaver JL, Szabo G Jr, Pine PS, Gottesman MM, Goldenberg S, Aszalos A (1993) The effect of ion channel blockers, immunosuppressive agents, and other drugs on the activity of the multi-drug transporter. Int J Cancer 54:456–461
Spengler G, Evaristo M, Handzlik J, Serly J, Molnar J, Viveiros M, Kiec-Kononowicz K, Amaral L (2010) Biological activity of hydantoin derivatives on P-glycoprotein (ABCB1) of mouse lymphoma cells. Anticancer Res 30:4867–4871
Cornwell MM, Pastan I, Gottesman MM (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166–2170
Koizumi S, Konishi M, Ichihara T, Wada H, Matsukawa H, Goi K, Mizutani S (1995) Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123. Eur J Cancer 31A:1682–1688
Molnar J, Szabo D, Mandi Y, Mucsi I, Fischer J, Varga A, Konig S, Motohashi N (1998) Multidrug resistance reversal in mouse lymphoma cells by heterocyclic compounds. Anticancer Res 18:3033–3038
Orlowski S, Mir LM, Belehradek J Jr, Garrigos M (1996) Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J 317(Pt 2):515–522
Spengler G, Takacs D, Horvath A, Riedl Z, Hajos G, Amaral L, Molnar J (2014) Multidrug resistance reversing activity of newly developed phenothiazines on P-glycoprotein (ABCB1)-related resistance of mouse T-lymphoma cells. Anticancer Res 34:1737–1741
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Armada, A. et al. (2016). Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter. In: Rueff, J., Rodrigues, A. (eds) Cancer Drug Resistance. Methods in Molecular Biology, vol 1395. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3347-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3347-1_7
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3345-7
Online ISBN: 978-1-4939-3347-1
eBook Packages: Springer Protocols